|
Patient survival overall and by Okuda stage and CLIP score |
||||||
| Thymostimulin (present data) |
Okuda et al. 1985 [16] |
CLIP 2000 [17] |
||||
|
|
||||||
| 1-year survival |
2-year survival |
1-year survival |
2-year survival |
1-year survival |
2-year survival |
|
|
|
||||||
| Overall |
50 % |
23 % |
26 % |
15 % |
48 % |
28 % |
| Okuda stage |
||||||
| I |
69 % |
38 % |
49 % |
32 % |
68 % |
48 % |
| II |
40 % |
11 % |
18 % |
9 % |
36 % |
13 % |
| III |
0 %* |
0 %* |
3 % |
3 % |
21 % |
10 % |
| CLIP score |
||||||
| 0 |
100 %* |
100 %* |
84 % |
65 % |
||
| 1 |
70 % |
40 % |
66 % |
45 % |
||
| 2 |
60 % |
20 % |
45 % |
17 % |
||
| 3 |
30 % |
10 % |
36 % |
12 % |
||
| 4–6 |
14 %* |
0 %* |
9 % |
0 % |
||
|
* small case number | ||||||
Dollinger et al. BMC Cancer 2008 8:72 doi:10.1186/1471-2407-8-72 |
||||||